14 results about "MRSA infection" patented technology

The invention discloses preparation and application of an anti-staphylococcus aureus IsdB antibody. The antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 8; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO: 16. The invention also provides nucleic acid for coding the antibody, a vector containing the nucleic acid and a cell containing the vector. In addition, experiments prove that the antibody can inhibit systemic infection of MRSA and resist invasion of MRSA to pneumonia, and has a good clinical application prospect.

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention discloses a microenvironment response type chessboard microneedle system and application thereof in treatment of drug-resistant bacteria infected wounds, and provides the microneedle system for solving the technical problems that in treatment of MRSA infected wounds, drugs are difficult to penetrate through wound surfaces and biological membrane barriers, the effective concentration of NO is difficult to maintain, and antibacterial-repair synergy is insufficient. The microneedle is formed by alternating hyaluronic acid and polyvinyl alcohol, ZCSO nano-enzyme and NO donor SNAP are loaded on the microneedle respectively, and the microneedle can penetrate through a physical barrier to accurately deliver functional components to a focus to achieve space targeting. The nidus microenvironment is triggered to release Cu < 2 + >, SNAP is catalyzed to continuously produce NO, time-space synchronization of NO and Cu < 2 + > is realized, and the NO gas therapy and copper-like death are used for synergistically resisting bacteria; se and Zn < 2 + > can relieve oxidative stress, regulate and control inflammation microenvironment and promote tissue regeneration. The system can efficiently remove MRSA and promote wound repair, provides a new strategy for treatment of drug-resistant bacteria infected wounds, and has a good clinical application prospect.

The invention belongs to the technical field of application of microorganisms, and particularly relates to a strain of streptomyces endogenus WA10-1-8 in intestinal tracts of cockroaches and application of a metabolic secondary product streptopherol compound of the streptomyces endogenus WA10-1-8 in anti-MRSA (Methicillin Resistant Staphylococcus Aureus) drugs. The cockroach intestinal endophytic streptomyces WA10-1-8 provided by the invention has the taxonomic name of Streptomyces albovinaceus, is preserved in Guangdong Microbial Culture Collection Center on June 13, 2024, and has the preservation number of GDMCC No: 4.422; the streptomyces WA10-1-8 is a symbiotic bacterium which is separated and screened from intestinal tracts of insect cockroaches; a metabolic secondary product, namely a streptophezine compound, has a relatively strong inhibition effect on MRSA (Methicillin-Resistant Staphylococcus Aureus), and can be used for preparing a medicine for treating MRSA infection.

The application discloses a p-hydroxycinnamaldehyde modified sphingomyelin liposome and application thereof in anti-MRSA infection. The p-hydroxycinnamaldehyde is bonded with the sphingomyelin through a two-step esterification reaction to obtain a bonding product sphingomyelin-p-hydroxycinnamaldehyde, and the p-hydroxycinnamaldehyde modified sphingomyelin liposome is prepared through a film hydration method. The liposome provided by the application is spherical, and the particle size distribution is uniform. The sphingomyelin component in the liposome can effectively neutralize the exotoxin of MRSA, and relieve the damage of the exotoxin of MRSA to normal cells of the body. The p-hydroxycinnamaldehyde in the liposome can induce the M0 type and M2 type macrophages in the body to polarize into M1 type macrophages with stronger phagocytosis and killing ability, relieve the immunosuppression caused by MRSA infection, and enhance the clearance ability of the macrophages to MRSA. The liposome provided by the application has application prospects in the preparation of drugs or preparations for treating diseases caused by MRSA infection.

The invention belongs to the technical field of biological pharmacy, and provides a piceatannol nano delivery particle based on chitosan oligosaccharide as well as a preparation method and application of the piceatannol nano delivery particle. The piceatannol nano delivery particle disclosed by the invention is a chitosan oligosaccharide nano drug-loaded particle modified by hyaluronic acid and D-tyrosine; the chitosan oligosaccharide nano drug-loaded particles comprise a chitosan oligosaccharide nano particle carrier and piceatannol wrapped in the chitosan oligosaccharide nano particle carrier. The hyaluronic acid and the D-tyrosine are adopted to carry out functional modification on the chitosan oligosaccharide nano drug-loaded particles, the hyaluronic acid realizes targeted delivery of MRSA infected parts, and the D-tyrosine has a biological membrane dispersing capacity, destroys a biological membrane structure, promotes a drug to deeply permeate into a biological membrane and improves an MRSA infection resisting effect; the antibacterial and anti-biofilm activity of piceatannol to MRSA (Methicillin Resistant Staphylococcus Aureus) is enhanced, and stronger antibacterial ability is shown; the lung bacterial load can be obviously reduced, the inflammatory lung injury can be relieved, and the treatment effect of resisting MRSA infection can be enhanced.

The invention discloses two novel cytochalasin compounds with activity of inhibiting methicillin-resistant staphylococcus aureus (MRSA) and application of the cytochalasin compounds. The invention provides a compound shown as a formula (I) or a compound shown as a formula (II). The compound shown in the formula (I) is named as a compound Aizuchalasin A. The invention further discloses a preparation method of the compound. The compound shown in the formula (II) is named as a compound Aizuchlaasin B. The formula (I) is shown in the description. The compound A and the compound B of the Aizuchalasin have the activity of inhibiting methicillin-resistant staphylococcus aureus. The invention provides a lead compound for developing a new anti-MRSA medicine, and has great value for treating MRSA infection.

The present invention relates to the use of punicalagin, such as anti-inflammatory and / or anti-Staphylococcus aureus, in particular anti-MRSA infection, including local and systemic infections, such as septicopyemia. Preferably, the medicine is combined with beta-lactam for use. The applicant discovers that PA can resist inflammation, has a unique staphylococcus aureus resisting mechanism, and is not easy to cause evolution and drug resistance of the staphylococcus aureus.

The invention provides application of a venenum bufonis extract combined with beta-lactam antibiotics in medicines for treating MRSA infection, and belongs to the technical field of biological medicines. The invention proves that the active ingredients of the venenum bufonis have strong affinity and are stably combined with target proteins such as PBP2a, BlaZ and AgrA of MRSA, so that the antibacterial effect of antibiotics is enhanced. The venenum bufonis extract and beta-lactam antibiotics are combined for use, so that a remarkable synergistic effect is achieved, and the drug resistance of drug-resistant staphylococcus aureus is overcome. Mouse model experiments prove that the venenum bufonis and penicillin G combined treatment has a remarkable treatment effect on MRSA infected mice. The combined application of the venenum bufonis and the penicillin G can effectively control the MRSA infection, and a novel and effective treatment scheme is provided.

The invention provides a high-dispersity berberine nano bacteriostatic agent which is characterized by comprising the following components in percentage by mass: 5-15% of berberine, 3-8% of a composite dispersant, 1-3% of a stabilizer and the balance of a solvent, the targeted enrichment mechanism of the nanoparticles and the bacteriostatic activity of berberine cooperate, efficient prevention and treatment of animal staphylococcal diseases are achieved, and especially for MRSA infection, the specific application scheme is as follows: the action mechanism is innovated: the nanoparticles (50-200 nm) can be mediated and internalized through the hydrophobic interaction of a phospholipid bilayer on the surface of a bacterial cell membrane, and the antibacterial activity of berberine is enhanced; the preparation method has the advantages that bacterial cell membrane barriers are broken through, the concentration of berberine in bacterial cells is increased by 40%-60%, the intracellular sterilization effect is obviously enhanced, and the problems that traditional berberine is difficult to penetrate through bacterial cell membranes and the effect on stubborn infection is poor are solved.

The application belongs to the technical field of medicine and pharmacy, and particularly relates to application of vincaleukoblastine in preparation of MRSA beta-lactamase inhibitors. The application of the vincaleukoblastine in preparation of MRSA infection treatment drugs, and the vincaleukoblastine can inhibit MRSA biofilm formation. The application discloses that the vincaleukoblastine can effectively restore the antibacterial activity of beta-lactam antibiotics, inhibit MRSA biofilm, and effectively treat MRSA infection mice.

This invention relates to a novel methicillin-resistant Staphylococcus aureus (MRSA) bacteriophage and its applications. The invention provides a methicillin-resistant MRSA bacteriophage SP01, which is identified as a new species. This phage possesses highly efficient lytic ability against MRSA and has a broad host spectrum, showing sensitivity to multiple clinical isolates. Furthermore, phage SP01 exhibits excellent environmental stability, maintaining good activity within a temperature range of 4–40°C and a pH range of 7–11. In summary, this invention allows for the preparation of drugs, disinfectants, and bactericides for treating MRSA infections using phage SP01, addressing the problem of conventional antibiotic ineffectiveness and demonstrating broad application prospects.

This invention relates to the field of pharmaceutical synthesis technology, specifically disclosing a 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative and its general structural formula; it also discloses the preparation method and application of this derivative. This 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative exhibits good inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and can be used to prevent and treat diseases caused by MRSA infection. Preferably, these diseases include, but are not limited to, pneumonia, urinary tract infections, bacteremia, sepsis, and suppurative arthritis caused by MRSA in humans and animals. The beneficial effects of this invention are: the 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative of this invention is obtained through a four-step reaction, the preparation method is simple, and the reaction conditions are mild; it has good inhibitory and bactericidal activity against MRSA and can be used to prevent and treat diseases caused by MRSA infection.

The invention discloses an antibacterial protein nano-drug delivery system as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method of the antibacterial protein nano drug delivery system comprises the following steps: carrying out mixed reaction on liposome encapsulating antibacterial protein CB6-C and an erythrocyte membrane to obtain RBCM-CB6-C-NLCs liposome; the RBCM-CB6-C-NLCs liposome and a PBP2a monoclonal antibody are subjected to a mixed reaction, and the antibacterial protein nano drug delivery system is obtained; the amino acid sequence of the antibacterial protein CB6-C is as shown in SEQ ID NO. 1. The drug delivery system provided by the invention can achieve the purposes of slowly releasing drugs, avoiding immune cell phagocytosis and actively targeting MRSA, has good safety and bactericidal activity, and has a good treatment effect on MRSA infection.